Glaxosmithkline Pharmaceuticals slips after Q3 PAT drops 4% YoY to Rs 150 cr


Glaxosmithkline Pharmaceuticals lost 1.42% to Rs 1,558 after the company’s consolidated net profit slipped 3.9% to Rs 150.35 crore on a 3% increase in net sales to Rs 815.92 crore in Q3 December 2021 compared to Q3 December 2020.

Consolidated profit before tax (PBT) slipped 9.9% to Rs 183.83 crore in Q3 FY22 from Rs 203.99 crore in Q3 FY21.

Revenue for the quarter from continuing operations was Rs 808 crore, recording a 2% year-on-year growth. PBT (before exceptional items) from continuing operations for the quarter amounted to Rs 189 crore, registering a 6% increase year-on-year. EBITDA from continuing operations was Rs 197 crore, recording an increase of 8% year-on-year.

Commenting on the third quarter results, Sridhar Venkatesh, Chief Executive Officer (MD) of GlaxoSmithKline Pharmaceuticals, said: “GSK’s established pharmaceutical portfolio delivered strong double-digit growth, driven by our core legacy brands such as Calpol, Augmentin and Ceftum.

“While our promoted brands have grown, our vaccines business has been impacted by the third wave of the pandemic. However, as this phase of the pandemic recedes and schools open across the country, we are seeing continued adoption of vaccination. We also continued to invest in our brands and educate parents about the most innovative vaccines in our portfolio.”

“During the quarter, we completed the sale of the Vemgal plant in Karnataka. Over the following quarters, we will also aim to complete the transfer of the lodex and Ostocalcium brands to GlaxoSmithKline Asia, as part of GSK’s plans to pie aiming to create two world-class companies in pharmaceuticals and consumer healthcare.”

At its meeting, the board of directors appointed Juby Chandy full-time director and chief financial officer (CFO) of the company for a period of three years from April 1, 2022. He succeeds Ms. Thakur who holds a position of financial management within the GSK group.

GSK Pharma is a subsidiary of GlaxoSmithKline plc, one of the world’s leading research-based pharmaceutical and healthcare companies.

Powered by Capital Market – Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor


Comments are closed.